08:57 AM EDT, 04/16/2024 (MT Newswires) -- Cybin ( CYBN ) said Tuesday the United States Patent and Trademark Office has awarded US patent 11,958,807 for its CYB003 program in treating major depressive disorder.

The patent, offering exclusivity until at least 2041, includes pharmaceutical compositions under Cybin's ( CYBN ) proprietary deuterated psilocybin analog program, CYB003.

Cybin ( CYBN ) shares rose more than 2% in premarket trading.